search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Comparisson of HistoScannnig guided prostate biopsy with systematic prostate biopsy in the detection of prostate cancer.


- candidate number8091
- NTR NumberNTR2342
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR27-mei-2010
- Secondary IDsMEC-2010-007 / NL30800.078.09 METC Erasmus MC / CCMO
- Public TitleComparisson of HistoScannnig guided prostate biopsy with systematic prostate biopsy in the detection of prostate cancer.
- Scientific TitleA pilot study to compare HistoScanning guided prostate biopsy with systematic biopsy in the detection of prostate cancer.
- ACRONYMHSGB
- hypothesisIn this study we will evalute the potention of HistoScanning guided biopsy to increase the detection rate of prostate cancer.
- Healt Condition(s) or Problem(s) studiedProstate cancer, Prostate biopsy, Computer aided ultrasonography
- Inclusion criteria1. Male patient aged ≥ 40 years;
2. Patient with a clinical suspicion of prostate cancer and scheduled for first bioptic procedure or patient who already received one systematic biopsy procedure with negative results currently under follow-up procedure due to a persistent indication;
3. Provides written informed consent and is willing and able to comply with protocol requirements.
- Exclusion criteria1. A history of previous prostate surgery;
2. Clinically apparent prostatitis within one month of biopsy;
3. Active urinary tract infection;
4. Has received a bioptic procedure within 30 days before admission into this study;
5. Incapable of understanding the language in which the information for the patient is given.
- mec approval receivedyes
- multicenter trialyes
- randomisedno
- groupFactorial
- TypeSingle arm
- Studytypeobservational
- planned startdate 26-apr-2010
- planned closingdate30-jul-2010
- Target number of participants30
- InterventionsThere will be no intervention. Patients undergo systematic and guided biopsies (invasive measurement).
- Primary outcomeBinary variable in terms of benign or malignant.
- Secondary outcome1. Gleason score;
2. Proportion of positive biopsy cores.
- TimepointsThere will be no follow-up. Patients visit the clinic once for the combined systematic and guided biopsy procedure.
- Trial web siteN/A
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIESDrs. S. Heuvel, van den
- CONTACT for SCIENTIFIC QUERIESDrs. S. Heuvel, van den
- Sponsor/Initiator Erasmus Medical Center, Department of Urology
- Funding
(Source(s) of Monetary or Material Support)
Erasmus Medical Center, Department of Urology
- PublicationsN/A
- Brief summaryRationale:
Biopsies are taken systematically from the prostate without an imaging technique that allows us to visualize areas suspicious of cancer. Various studies conducted have shown that up to 35% of all clinically significant prostate cancers are not detected by systematic biopsy. In this study we will evaluate the potential of HistoScanningTM guided biopsy to increase the detection rate of prostate cancer.

Objective:
The primary objective of this study is to compare HistoScanningTM guided prostate biopsy with systematic biopsy in the detection of prostate cancer in men candidate for a first or second biopsy procedure.

Study design:
Observational pilot study.

Study population:
Men ≥ 40 years old with a clinical suspicion of prostate cancer and candidate for a bioptic procedure. The study population comprises both candidates for a first bioptic exam and candidates for a second bioptic procedure having a previous negative result independently from the present study.

Study procedure:
Patients will receive a HistoScanning prior to the biopsy procedure. In case one or more lesions of ≥ 0.2 cm3 are seen with HistoScanning a maximum of 4 HistoScanning guided prostate biopsy cores are taken in addition to the standard systematic prostate biopsies (8, 10 or 12 biopsies, dependent on prostate volume).

Main study parameters/endpoints:
Number of standard and HistoScanning guided cores, number of positive standard and HistoScanning guided cores, length of standard and HistoScanning guided core, % of standard and HistoScanning guided core infiltrated with cancer, Gleason score of standard and HistoScanning guided biopsies, prostate volume, baseline PSA, PSA density, results of digital rectal examination (DRE), TRUS and HistoScanning analysis.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
The HistoScanning procedure should, from the patientís perspective, be no different from standard diagnostic transrectal ultrasonography. The systematic and HistoScanning guided biopsy will be performed in the same session, so no extra visit is required. A maximum of 4 HistoScanning guided biopsy cores will be performed in addition to the standard systematic biopsy. Accordingly the number of bioptic cores taken in this study will not exceed 16.
- Main changes (audit trail)
- RECORD27-mei-2010 - 5-jun-2010


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl